Clinical Trial Update: Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine [Phase 2]

View source ↗

Summary

Phase 2 study of brentuximab vedotin in relapsed/refractory peripheral T-cell lymphoma treated with gemcitabine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Adcetris) (brentuximab vedotin)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 2 | Status: COMPLETED